Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Double-blind, Placebo-controlled, Parallel Study of PH94B Nasal Spray in the Treatment of Adjustment Disorder With Anxiety

NCT04404192 is registered in ClinicalTrials.gov with VistaGen Therapeutics, Inc. as lead sponsor.

NCT NCT04404192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04404192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Double-blind, Placebo-controlled, Parallel Study of PH94B Nasal Spray in the Treatment of Adjustment Disorder With Anxiety
Lead sponsor
VistaGen Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 12, 2021
Completion date
December 14, 2022
Enrollment
41 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adjustment disorder with anxious mood